Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy
Author(s) -
Betül Dündar,
Burcu Dinçgez Çakmak,
Gülten Özgen,
Fatma Ketenci Gencer,
Burcu Aydın Boyama
Publication year - 2017
Publication title -
the european research journal
Language(s) - English
Resource type - Journals
ISSN - 2149-3189
DOI - 10.18621/eurj.304373
Subject(s) - medicine , mucositis , methotrexate , lethargy , bone marrow suppression , vomiting , ectopic pregnancy , rash , bone marrow , leukopenia , surgery , nausea , chemotherapy , gastroenterology , pregnancy , biology , genetics
Methotrexate is associated with multisystem side effects which depend on the dosage, route of administration and length of treatment. Bone marrow suppression is a very rare but one of the most mortal complications. A case of severe bone marrow suppression following single dose methotrexate for ectopic pregnancy was presented in this study. A 33-year-old woman, diagnosed as ectopic pregnancy, was given single-dose intramuscular methotrexate of 50 mg/m². On 10 th day patient was admitted with lethargy, irritability, vomiting, hematemesis, diarrhea, oral mucositis and skin rash. Laboratory findings revealed severe bone marrow suppression. Supportive treatment together with antibacterial/ antifungal drugs and granulocyte colony stimulating factors were administered. On the 3 rd day of treatment, mucositis and oral intake began to improve. After 1 week complete blood count was normal. Methotrexate may have mortal clinical consequences even with very low doses. Therefore, a careful patient history for patient selection and closer clinical follow-up are essential.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom